Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.…
Bacteriophage Therapy - Global Strategic Business Report 2026: Capture the $1.6 Billion 2032 Market with Adaptive Phage Therapeutics, Armata Pharmaceuticals, BiomX, and Locus Biosciences
Armata Pharmaceuticals (NYSEAMERICAN: ARMP) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 61 employees.
The shares were at 3.030 USD on 20 November 2026, down 39.3% over 52 weeks. Its 52-week range is 2.400 USD to 14.98 USD: the price is 79.8% below the high and 26.2% above the low.
Its market capitalisation is 112.69M USD.
Armata Pharmaceuticals reports return on equity of 79.5%, an operating margin of -461.8% and revenue up 173.6% year over year.
Its debt exceeds its cash by 233.27M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 24 March 2027.